Scientific and Regulatory Policy Committee Points-to-consider Paper: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics
Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics...
Gespeichert in:
| Veröffentlicht in: | Toxicologic pathology 2015-10, Vol.43 (7), p.915-934 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 934 |
|---|---|
| container_issue | 7 |
| container_start_page | 915 |
| container_title | Toxicologic pathology |
| container_volume | 43 |
| creator | Frazier, Kendall S. Engelhardt, Jeffery A. Fant, Pierluigi Guionaud, Silvia Henry, Scott P. Leach, Michael W. Louden, Calvert Scicchitano, Marshall S. Weaver, James L. Zabka, Tanja S. |
| description | Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics such as peptides/proteins or antibodies. Because of the uncertainty about whether DIVI in preclinical studies is predictive of effects in humans and the lack of robust biomarkers of DIVI, preclinical DIVI findings can cause considerable delays in or even halt development of promising new drugs. This review discusses standard terminology, characteristics, and mechanisms of DIVI associated with biotherapeutics. Guidance and points to consider for the toxicologist and pathologist facing preclinical cases of biotherapeutic-related DIVI are outlined, and examples of regulatory feedback for each of the mechanistic types of DIVI are included to provide insight into risk assessment. |
| doi_str_mv | 10.1177/0192623315570340 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1718906600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0192623315570340</sage_id><sourcerecordid>1718906600</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-c9b56cdff67fafec8c6de006d58e08eafec65909754ecf58942f2cb8ee7b71123</originalsourceid><addsrcrecordid>eNp1kM1LxDAUxIMo7rp69yQ9eqm-pE3SHmXxCxZc_DiXNH1ZsrTNmqSH_e9tWfUgeHow85uBN4RcUrihVMpboCUTLMso5xKyHI7InPIsS6kAekzmk51O_oychbAFoAXN4ZTMGJeMUcbmZPmmLfbRGqsT1TfJK26GVkXn98natVbvk6XrOhsj4ijYPoY0ulS7PtgGfbJWO_Tn5MSoNuDF912Qj4f79-VTunp5fF7erVLNSoipLmsudGOMkEYZ1IUWDQKIhhcIBU6S4CWUkueoDS_KnBmm6wJR1pJSli3I9aF3593ngCFWnQ0a21b16IZQUUmLEoQAGFE4oNq7EDyaaudtp_y-olBN01V_pxsjV9_tQ91h8xv42WoE0gMQ1AarrRt8P377f-EXf_F2Iw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1718906600</pqid></control><display><type>article</type><title>Scientific and Regulatory Policy Committee Points-to-consider Paper: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><source>Alma/SFX Local Collection</source><creator>Frazier, Kendall S. ; Engelhardt, Jeffery A. ; Fant, Pierluigi ; Guionaud, Silvia ; Henry, Scott P. ; Leach, Michael W. ; Louden, Calvert ; Scicchitano, Marshall S. ; Weaver, James L. ; Zabka, Tanja S.</creator><creatorcontrib>Frazier, Kendall S. ; Engelhardt, Jeffery A. ; Fant, Pierluigi ; Guionaud, Silvia ; Henry, Scott P. ; Leach, Michael W. ; Louden, Calvert ; Scicchitano, Marshall S. ; Weaver, James L. ; Zabka, Tanja S. ; Society of Toxicologic Pathology Vascular Injury Working Group</creatorcontrib><description>Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics such as peptides/proteins or antibodies. Because of the uncertainty about whether DIVI in preclinical studies is predictive of effects in humans and the lack of robust biomarkers of DIVI, preclinical DIVI findings can cause considerable delays in or even halt development of promising new drugs. This review discusses standard terminology, characteristics, and mechanisms of DIVI associated with biotherapeutics. Guidance and points to consider for the toxicologist and pathologist facing preclinical cases of biotherapeutic-related DIVI are outlined, and examples of regulatory feedback for each of the mechanistic types of DIVI are included to provide insight into risk assessment.</description><identifier>ISSN: 0192-6233</identifier><identifier>EISSN: 1533-1601</identifier><identifier>DOI: 10.1177/0192623315570340</identifier><identifier>PMID: 25722122</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Animals ; Disease Models, Animal ; Drug Evaluation, Preclinical - methods ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Vascular System Injuries - chemically induced</subject><ispartof>Toxicologic pathology, 2015-10, Vol.43 (7), p.915-934</ispartof><rights>2015 by The Author(s)</rights><rights>2015 by The Author(s).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c290t-c9b56cdff67fafec8c6de006d58e08eafec65909754ecf58942f2cb8ee7b71123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0192623315570340$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0192623315570340$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21799,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25722122$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frazier, Kendall S.</creatorcontrib><creatorcontrib>Engelhardt, Jeffery A.</creatorcontrib><creatorcontrib>Fant, Pierluigi</creatorcontrib><creatorcontrib>Guionaud, Silvia</creatorcontrib><creatorcontrib>Henry, Scott P.</creatorcontrib><creatorcontrib>Leach, Michael W.</creatorcontrib><creatorcontrib>Louden, Calvert</creatorcontrib><creatorcontrib>Scicchitano, Marshall S.</creatorcontrib><creatorcontrib>Weaver, James L.</creatorcontrib><creatorcontrib>Zabka, Tanja S.</creatorcontrib><creatorcontrib>Society of Toxicologic Pathology Vascular Injury Working Group</creatorcontrib><title>Scientific and Regulatory Policy Committee Points-to-consider Paper: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics</title><title>Toxicologic pathology</title><addtitle>Toxicol Pathol</addtitle><description>Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics such as peptides/proteins or antibodies. Because of the uncertainty about whether DIVI in preclinical studies is predictive of effects in humans and the lack of robust biomarkers of DIVI, preclinical DIVI findings can cause considerable delays in or even halt development of promising new drugs. This review discusses standard terminology, characteristics, and mechanisms of DIVI associated with biotherapeutics. Guidance and points to consider for the toxicologist and pathologist facing preclinical cases of biotherapeutic-related DIVI are outlined, and examples of regulatory feedback for each of the mechanistic types of DIVI are included to provide insight into risk assessment.</description><subject>Animals</subject><subject>Disease Models, Animal</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Humans</subject><subject>Vascular System Injuries - chemically induced</subject><issn>0192-6233</issn><issn>1533-1601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1LxDAUxIMo7rp69yQ9eqm-pE3SHmXxCxZc_DiXNH1ZsrTNmqSH_e9tWfUgeHow85uBN4RcUrihVMpboCUTLMso5xKyHI7InPIsS6kAekzmk51O_oychbAFoAXN4ZTMGJeMUcbmZPmmLfbRGqsT1TfJK26GVkXn98natVbvk6XrOhsj4ijYPoY0ulS7PtgGfbJWO_Tn5MSoNuDF912Qj4f79-VTunp5fF7erVLNSoipLmsudGOMkEYZ1IUWDQKIhhcIBU6S4CWUkueoDS_KnBmm6wJR1pJSli3I9aF3593ngCFWnQ0a21b16IZQUUmLEoQAGFE4oNq7EDyaaudtp_y-olBN01V_pxsjV9_tQ91h8xv42WoE0gMQ1AarrRt8P377f-EXf_F2Iw</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Frazier, Kendall S.</creator><creator>Engelhardt, Jeffery A.</creator><creator>Fant, Pierluigi</creator><creator>Guionaud, Silvia</creator><creator>Henry, Scott P.</creator><creator>Leach, Michael W.</creator><creator>Louden, Calvert</creator><creator>Scicchitano, Marshall S.</creator><creator>Weaver, James L.</creator><creator>Zabka, Tanja S.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Scientific and Regulatory Policy Committee Points-to-consider Paper</title><author>Frazier, Kendall S. ; Engelhardt, Jeffery A. ; Fant, Pierluigi ; Guionaud, Silvia ; Henry, Scott P. ; Leach, Michael W. ; Louden, Calvert ; Scicchitano, Marshall S. ; Weaver, James L. ; Zabka, Tanja S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-c9b56cdff67fafec8c6de006d58e08eafec65909754ecf58942f2cb8ee7b71123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Disease Models, Animal</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Humans</topic><topic>Vascular System Injuries - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frazier, Kendall S.</creatorcontrib><creatorcontrib>Engelhardt, Jeffery A.</creatorcontrib><creatorcontrib>Fant, Pierluigi</creatorcontrib><creatorcontrib>Guionaud, Silvia</creatorcontrib><creatorcontrib>Henry, Scott P.</creatorcontrib><creatorcontrib>Leach, Michael W.</creatorcontrib><creatorcontrib>Louden, Calvert</creatorcontrib><creatorcontrib>Scicchitano, Marshall S.</creatorcontrib><creatorcontrib>Weaver, James L.</creatorcontrib><creatorcontrib>Zabka, Tanja S.</creatorcontrib><creatorcontrib>Society of Toxicologic Pathology Vascular Injury Working Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Toxicologic pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frazier, Kendall S.</au><au>Engelhardt, Jeffery A.</au><au>Fant, Pierluigi</au><au>Guionaud, Silvia</au><au>Henry, Scott P.</au><au>Leach, Michael W.</au><au>Louden, Calvert</au><au>Scicchitano, Marshall S.</au><au>Weaver, James L.</au><au>Zabka, Tanja S.</au><aucorp>Society of Toxicologic Pathology Vascular Injury Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scientific and Regulatory Policy Committee Points-to-consider Paper: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics</atitle><jtitle>Toxicologic pathology</jtitle><addtitle>Toxicol Pathol</addtitle><date>2015-10</date><risdate>2015</risdate><volume>43</volume><issue>7</issue><spage>915</spage><epage>934</epage><pages>915-934</pages><issn>0192-6233</issn><eissn>1533-1601</eissn><abstract>Drug-induced vascular injury (DIVI) is a recurrent challenge in the development of novel pharmaceutical agents. Although DIVI in laboratory animal species has been well characterized for vasoactive small molecules, there is little available information regarding DIVI associated with biotherapeutics such as peptides/proteins or antibodies. Because of the uncertainty about whether DIVI in preclinical studies is predictive of effects in humans and the lack of robust biomarkers of DIVI, preclinical DIVI findings can cause considerable delays in or even halt development of promising new drugs. This review discusses standard terminology, characteristics, and mechanisms of DIVI associated with biotherapeutics. Guidance and points to consider for the toxicologist and pathologist facing preclinical cases of biotherapeutic-related DIVI are outlined, and examples of regulatory feedback for each of the mechanistic types of DIVI are included to provide insight into risk assessment.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>25722122</pmid><doi>10.1177/0192623315570340</doi><tpages>20</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0192-6233 |
| ispartof | Toxicologic pathology, 2015-10, Vol.43 (7), p.915-934 |
| issn | 0192-6233 1533-1601 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1718906600 |
| source | MEDLINE; SAGE Complete A-Z List; Alma/SFX Local Collection |
| subjects | Animals Disease Models, Animal Drug Evaluation, Preclinical - methods Drug-Related Side Effects and Adverse Reactions Humans Vascular System Injuries - chemically induced |
| title | Scientific and Regulatory Policy Committee Points-to-consider Paper: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T22%3A10%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scientific%20and%20Regulatory%20Policy%20Committee%20Points-to-consider%20Paper:%20Drug-induced%20Vascular%20Injury%20Associated%20with%20Nonsmall%20Molecule%20Therapeutics%20in%20Preclinical%20Development:%20Part%20I.%20Biotherapeutics&rft.jtitle=Toxicologic%20pathology&rft.au=Frazier,%20Kendall%20S.&rft.aucorp=Society%20of%20Toxicologic%20Pathology%20Vascular%20Injury%20Working%20Group&rft.date=2015-10&rft.volume=43&rft.issue=7&rft.spage=915&rft.epage=934&rft.pages=915-934&rft.issn=0192-6233&rft.eissn=1533-1601&rft_id=info:doi/10.1177/0192623315570340&rft_dat=%3Cproquest_cross%3E1718906600%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1718906600&rft_id=info:pmid/25722122&rft_sage_id=10.1177_0192623315570340&rfr_iscdi=true |